Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Sugemalimab plus chemotherapie verbetert overleving bij gevorderde maagkanker
jun 2025 | Immuuntherapie, Maag-darm-leveroncologie